


9/26/05

L4 ANSWER 16 OF 20 CAPLUS COPYRIGHT 2005 ACS on STN
GI



AB The title compds. I [R = H, (substituted) alkyl, alkenyl, cycloalkyl, haloalkyl; R3 = H, alkyl, aryl; R4 = (substituted) alkyl, alkenyl, cycloalkyl, (substituted) aryl; R5 = H, halo, alkyl, alkoxy, NO2], useful as antiinflammatory agents, were prepared by cyclization of II in the presence of polyphosphoric acid. A mixture of 10 g 3-methyl-5-phenyl-4-pyrazolamine and 10 g PhCOCl in 100 mL CHCl3 was stirred at room temperature for

30 min to give 12 g N-(3-methyl-5-phenyl-4-pyrazolyl)benzamide (III). A mixture of 9 g III and 90 g polyphosphoric acid was heated at 200-300° for 15-30 min to give 7 g pyrazoloisoquinoline derivative I (R = R5 = H, R3 = Me, R4 = Ph) (IV). At 20 mg/kg orally, IV inhibited carrageenin-induced edema in rats by 48%. Tablets containing IV, lactose, starch, talc, and Mg stearate were prepared

AN 1988:94544 CAPLUS
DN 108:94544
TI Preparation of pyrazoloisoquinolines as antiinflammatory agents
IN Tully, Wilfred Roger
PA Roussel Laboratories Ltd., UK
SO Brit. UK Pat. Appl., 11 pp.
CODEN: BAXXDU
DT Patent
LA English
FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	GB 2185255	A1	19870715	GB 1987-662	19870113
	GB 2185255	B2	19891206		
	FR 2595096	A1	19870904	GB 1986-752	A 19860114
	FR 2595096	B1	19911129	FR 1987-152	19870109
				GB 1986-752	A 19860114

OS CASREACT 108:94544
IT 112884-48-7P, 3-Methyl-5-phenyl-1H-pyrazolo[4,3-c]isoquinoline
112884-49-8P 112884-50-1P 112884-53-4P
112884-54-5P 112884-55-6P 112884-56-7P
112884-57-8P 112884-58-9P 112884-59-0P
112913-70-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as antiinflammatory agent)
RN 112884-48-7 CAPLUS

10613588


9/26/05

CN 1H-Pyrazolo[4,3-c]isoquinoline, 3-methyl-5-phenyl- (9CI) (CA INDEX NAME)




RN 112884-49-8 CAPLUS

CN 1H-Pyrazolo[4,3-c]isoquinoline, 1,3-dimethyl-5-phenyl- (9CI) (CA INDEX NAME)




RN 112884-50-1 CAPLUS

CN 2H-Pyrazolo[4,3-c]isoquinoline, 2-ethyl-3-methyl-5-phenyl- (9CI) (CA INDEX NAME)



RN 112884-53-4 CAPLUS

CN 1H-Pyrazolo[4,3-c]isoquinoline, 3,5-dimethyl- (9CI) (CA INDEX NAME)




RN 112884-54-5 CAPLUS

CN 1H-Pyrazolo[4,3-c]isoquinoline, 3-methyl-5-(4-methylphenyl)- (9CI) (CA

10613588


9/26/05

INDEX NAME)




RN 112884-55-6 CAPLUS

CN 1H-Pyrazolo[4,3-c]isoquinoline, 5-methyl-3-phenyl- (9CI) (CA INDEX NAME)



RN 112884-56-7 CAPLUS


CN 1H-Pyrazolo[4,3-c]isoquinoline, 5-(4-chlorophenyl)-3-methyl- (9CI) (CA INDEX NAME)



RN 112884-57-8 CAPLUS


CN 1H-Pyrazolo[4,3-c]isoquinoline, 5-ethyl-3-methyl- (9CI) (CA INDEX NAME)

9/26/05




RN 112884-58-9 CAPLUS

CN 2H-Pyrazolo[4,3-c]isoquinoline, 2,3-dimethyl-5-phenyl- (9CI) (CA INDEX NAME)




RN 112884-59-0 CAPLUS

CN 1H-Pyrazolo[4,3-c]isoquinoline, 1-(3-chloropropyl)-3-methyl-5-phenyl- (9CI) (CA INDEX NAME)



RN 112913-70-9 CAPLUS

CN 2H-Pyrazolo[4,3-c]isoquinoline, 2-(3-chloropropyl)-3-methyl-5-phenyl- (9CI) (CA INDEX NAME)



L4 ANSWER 17 OF 20 CAPLUS COPYRIGHT 2005 ACS on STN

10613588